Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes

J An, GA Nichols, L Qian, MA Munis… - BMJ Open Diabetes …, 2021 - drc.bmj.com
Introduction Type 2 diabetes (T2D) is a common condition that, if left untreated or poorly
managed, can lead to adverse microvascular and macrovascular complications. We …

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

T Weiss, L Yang, RD Carr, S Pal, B Sawhney… - BMJ Open Diabetes …, 2022 - drc.bmj.com
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a type 2 diabetes
mellitus (T2DM) treatment with demonstrated weight loss benefits in clinical trials. However …

[BOOK][B] Reengineering performance management breakthroughs in achieving strategy through people

T Weiss, F Hartle - 2023 - books.google.com
Looking for the ultimate book to help reengineer the way your company manages
performance? Here is a major work that lays the groundwork for successful change at …

[BOOK][B] Coaching competencies and corporate leadership

T Weiss, S Kolberg - 2003 - books.google.com
The quality of corporate leadership is often the key factor that determines success-or failure-
in the fiercely competitive business world. Offering a fresh perspective and practical advice …

Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States

T Weiss, RD Carr, S Pal, L Yang… - Patient preference …, 2020 - Taylor & Francis
Aim To assess adherence and discontinuation of injectable glucagon-like peptide-1 receptor
agonists (GLP-1 RA) at 12 and 24 months among adult type 2 diabetes mellitus (T2DM) …

[HTML][HTML] Metformin adherence and discontinuation among patients with type 2 diabetes: a retrospective cohort study

Y Tang, T Weiss, J Liu, S Rajpathak, K Khunti - Journal of Clinical & …, 2020 - Elsevier
Aims To describe discontinuation and adherence to metformin in the United Kingdom.
Methods This was a retrospective analysis of data from the Clinical Practice Research …

Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.

M Pawaskar, P Bilir, S Kowal, Q Li… - American Journal of …, 2021 - search.ebscohost.com
OBJECTIVES: Using a US payer perspective, this study aimed to compare the lifetime cost-
effectiveness of adding sodium-glucose cotransporter 2 (SGLT2) inhibitors vs switching to …

Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes

J An, GA Nichols, L Qian, TN Harrison, Z Li… - Journal of Diabetes and …, 2020 - Elsevier
Objective To estimate time in suboptimal glycemic control among patients with incident type
2 diabetes (T2D) over 10 years. Methods We calculated percent of time in suboptimal …

984-P: real-world adherence and discontinuation of GLP-1 receptor agonist (GLP-1RA) therapy in type 2 diabetes (T2D) patients in the US

T Weiss, K Iglay, RD Carr, AP Mishra, L Yang… - Diabetes, 2019 - Am Diabetes Assoc
Background: GLP-1 RAs are an incretin-based, injectable, therapeutic option for the
treatment of T2D. However, there are limited data related to patients' adherence to, or …

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus

T Weiss, K Iglay, T Gulati, S Rajpathak… - BMJ Open Diabetes …, 2021 - drc.bmj.com
Introduction To assess secondary metformin monotherapy (MM) failure in a real-world type 2
diabetes mellitus (T2DM) cohort. Research design and methods Using the IQVIA Electronic …